Made in China: New and Potentially Lifesaving Drugs<br />Ms. Carney said she expected 20 or 30 Chinese-made drugs to seek Phase 3 trials in the United<br />States, the world’s biggest market for cancer drugs, within the next five years.<br />“The funds are chasing us,” she said, comparing the investment environment between China<br />and the United States, “instead of us having to spend numerous hours convincing investors.”<br />Despite the optimism, Chinese pharmaceutical companies that want to go abroad still face obstacles.<br />Laura Nelson Carney, an Asia-Pacific health care analyst at Bernstein Research, said<br />that based on the industry average, the probability of success in Phase 3 trials is 60 to 70 percent.<br />Along with Chi-Med, another company, BeiGene, is already in Phase 3 trials globally for a drug used to treat a variety of lymphomas, the most common form of blood cancer,<br />and an immunotherapy drug that aims to destroy tumors.<br />After 20 years in the United States with Eli Lilly and Pfizer, Joan Shen moved to Shanghai in 2011 to lead clinical trials for Pfizer.
